05Jun
What We Learned From FDA's Public Hearing On Cannabis
The much-anticipated public hearing last week at the U.S. Food and Drug Administration on cannabis and cannabis-derived compounds drew a wide audience of participants, with strong views on how the FDA should (or should not) regulate the controversial...
By:
Sheppard Mullin Richter & Hampton LLP
Related
The Federal Trade Commission (FTC) and Department of Justice (DOJ) have extended the deadline for pu...
Read More >
In a significant decision for employers, the National Labor Relations Board (NLRB) provided new guid...
Read More >
The use of non-competition agreements between employers and employees has raised concerns at the Fed...
Read More >
I want to emphasize again the risks JVs pose under the FCPA. Mike Volkov has stated, “A joint ventu...
Read More >
Employers throughout the U.S. are wrapping up October by participating in National Disability Employ...
Read More >
In HUMC Holdco, LLC et al v. MPT of Hoboken TRS, LLC et al, the Delaware Court of Chancery examined ...
Read More >